Your session is about to expire
← Back to Search
Antiretroviral
Open label for HIV
Phase 4
Waitlist Available
Research Sponsored by Southampton Healthcare, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights
Study Summary
This trial looks at whether it's safe to switch HIV medication for people who are already taking elvitegravir/tenofovir alafenamide/emtricitabine/cobicistat and darunavir, and who have a I84 V/I mutation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 48 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Secondary outcome measures
Test the safety and effectiveness of the drug Biktarvy in subjects known to have the 184
Test the safety and effectiveness of the drug Biktarvy in subjects known to have the 184 V/I resistance mutation.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Open labelExperimental Treatment1 Intervention
Open label Biktarvy to establish suppression of HIV 1 with 184 V/I Resistance Mutation
Find a Location
Who is running the clinical trial?
Southampton Healthcare, Inc.Lead Sponsor
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger